Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00873340 |
The purpose of this study is
Condition | Intervention |
---|---|
Multiple Sclerosis |
Drug: Interferon-1beta (Betaseron BAY86-5046) |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Physical Disability Observational Study in Patients Treated With Betaferon in Daily Practice |
Estimated Enrollment: | 100 |
Study Start Date: | October 2007 |
Estimated Study Completion Date: | December 2011 |
Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
Group 1 |
Drug: Interferon-1beta (Betaseron BAY86-5046)
Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
MS community sample
Inclusion Criteria:
Exclusion Criteria:
Contact: Bayer Clinical Trials Contact | clinical-trials-contact@bayerhealthcare.com |
Colombia | |
Recruiting | |
Many Locations, Colombia |
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Bayer Schering Pharma AG ( Medical Director ) |
Study ID Numbers: | 14173, BF0712CO |
Study First Received: | March 31, 2009 |
Last Updated: | August 31, 2009 |
ClinicalTrials.gov Identifier: | NCT00873340 History of Changes |
Health Authority: | Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos; United States: Food and Drug Administration |
MS Multiple Sclerosis Betaferon Colombia |
Autoimmune Diseases Multiple Sclerosis Immunologic Factors Demyelinating Diseases Interferons Adjuvants, Immunologic |
Interferon-beta Interferon beta-1b Demyelinating Autoimmune Diseases, CNS Sclerosis Autoimmune Diseases of the Nervous System |
Autoimmune Diseases Demyelinating Diseases Immune System Diseases Immunologic Factors Nervous System Diseases Physiological Effects of Drugs Adjuvants, Immunologic |
Sclerosis Pharmacologic Actions Multiple Sclerosis Pathologic Processes Interferon beta-1b Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System |